Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients With Severe Preeclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The following parameters of all patients were within the normal range: hematic biometry, urine and glucose tests, aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum creatinine, blood coagulation test including prothrombin time and activated partial thromboplastin time. Electrocardiogram and chest radiography showed no pathological data.~Exclusion Criteria:~When the patient falls outside of the aforementioned parameters, or subjects with unstable medical conditions.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Diltiazem (Type: EXPERIMENTAL): Postpartum patients were administered (60 mg) orally every 8 hours with diltiazem (tables).
- Nifedipine (Type: ACTIVE_COMPARATOR): Postpartum patients were administered (10 mg) orally every 8 hours with nifedipine (capsule).

Based on this trial design, predict the completion outcome and termination type (if applicable).